Peter K. Vogt

Scripps Research Institute — United States

Agricultural and Biological Sciences · Life Sciences

97h-index33.8kcitations491works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Animal Virus Infections Studies(117), Virus-based gene therapy research(101), Plant Virus Research Studies(72), PI3K/AKT/mTOR signaling in cancer(71), Herpesvirus Infections and Treatments(39)

Publications491 total

The constitutive oncogenic and signaling activities of phosphatidylinositol 3-kinase (PI3K) isoforms p110β and p110δ
2025Open Access
Long Non-Coding RNAs as “MYC Facilitators”
Pathophysiology·2023· 2 citedOpen Access
Structural insights into the interaction of three Y-shaped ligands with PI3Kα
Proceedings of the National Academy of Sciences·2023· 7 citedOpen Access
Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα)
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer·2023· 5 citedOpen Access
Supplementary Figure Legends 1-2 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Supplementary Figure 2 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Supplementary Figure 1 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Supplementary Data from Requirement of Phosphatidylinositol(3,4,5)Trisphosphate in Phosphatidylinositol 3-Kinase-Induced Oncogenic Transformation
2023Open Access
Supplementary Table 2 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Supplementary Table 2 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Supplementary Figure Legends 1-2 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Data from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Supplementary Figure 2 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Data from Requirement of Phosphatidylinositol(3,4,5)Trisphosphate in Phosphatidylinositol 3-Kinase-Induced Oncogenic Transformation
2023Open Access
Data from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
Data from Requirement of Phosphatidylinositol(3,4,5)Trisphosphate in Phosphatidylinositol 3-Kinase-Induced Oncogenic Transformation
2023Open Access
Supplementary Data from Requirement of Phosphatidylinositol(3,4,5)Trisphosphate in Phosphatidylinositol 3-Kinase-Induced Oncogenic Transformation
2023Open Access
Supplementary Figure 1 from PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
2023Open Access
The MYC-regulated lncRNA LNROP (ENSG00000254887) enables MYC-driven cell proliferation by controlling the expression of OCT2
Cell Death and Disease·2023· 6 citedOpen Access
Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα
Proceedings of the National Academy of Sciences·2022· 47 citedOpen Access
page 1 of 25Next →

Frequent Co-authors

Timothy J. Bos(7), Masahiro Aoki(7), Sohye Kang(4), Dirk Bohmann(3), Harold Varmus(3), J. Michael Bishop(3), Andreas G. Bader(3), Bing‐Hua Jiang(3), Lynn Ueno(3), Jonathan R. Hart(3), Peter Duesberg(3), Ryotaro Ishizaki(3), Robert Tjian(2), Jenny Z. Zheng(2), Michael J. Hayman(2), Alfonso Bellacosa(2), Philip N. Tsichlis(2), Robin A. Weiss(2), Robert R. Friis(2), Arie Admon(1)